Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.50
- Piotroski Score 2.00
- Grade Neutral
- Symbol (TALS)
- Company Talaris Therapeutics, Inc.
- Price $2.72
- Changes Percentage (-0.73%)
- Change -$0.02
- Day Low $2.69
- Day High $2.80
- Year High $3.29
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
- Last Earnings 10/19/2023
- Ex-Dividend for 5/16 Dividend 10/19/2023
- Dividend Payable 10/20/2023
- Today N/A
- Next Earnings (Estimated) 11/08/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.74
- Trailing P/E Ratio -1.5632183908046
- Forward P/E Ratio -1.5632183908046
- P/E Growth -1.5632183908046
- Net Income $-68,728,000
Income Statement
Quarterly
Annual
Latest News of TALS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Are Investors Undervaluing Aqua Metals, Inc. (NASDAQ:AQMS) By 36%?
Aqua Metals' undervaluation at US$2.50 per share suggests a potential 36% discount. The Discounted Cash Flow (DCF) model is used to estimate its investment attractiveness based on future cash flows di...
By Yahoo! Finance | 13 hours ago -
AQMS Stock Price | Aqua Metals Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
Aqua Metals, Inc. revolutionizes metal recycling through AquaRefining, an eco-friendly technology that retrieves metals from batteries using electricity instead of polluting methods. Founded in 2014 i...
By MarketWatch | 15 hours ago -
Is Netflix, Inc.'s (NASDAQ:NFLX) Recent Stock Performance Tethered To Its Strong Fundamentals?
Netflix's stock has surged by 24% in three months. The focus is on the Return on Equity (ROE), a measure of how efficiently a company utilizes capital....
By Yahoo! Finance | 1 day ago
